Drugs / PSA-3
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00030602 | Jan 2000 → Dec 2001 | prostate cancer | University of Maryland, Baltimore | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PSA-3 | “PSA-3 peptide vaccine emulsified in Montanide ISA-51” NCT00030602 ↗ |
| Modality | Vaccine | “PSA-3 peptide vaccine” NCT00030602 ↗ |
| Route | Subcutaneous | “Patients receive PSA-3 peptide vaccine emulsified in Montanide ISA-51 subcutaneously” NCT00030602 ↗ |